0001326190false00013261902024-08-132024-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2024

ALTIMMUNE, INC.

(Exact name of registrant as specified in its charter)

Delaware

 

001-32587

 

20-2726770

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

910 Clopper Road, Suite 201S

Gaithersburg, Maryland

20878

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number including area code: (240) 654-1450

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

ALT

The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On August 13, 2024, David J. Drutz, M.D. notified the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) that he has decided not to stand for re-election to the Board at the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”). Dr. Drutz will continue to serve as a director until the date of the Annual Meeting. Dr. Drutz’s decision not to stand for re-election was not due to any disagreement with the Company on a matter relating to the Company’s operations, policies or practices. The Board thanks Dr. Drutz for his service and contributions as a director.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

No.

  

Description

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALTIMMUNE, INC.

By:

 

/s/ Andrew Shutterly

 

Name: Andrew Shutterly

 

Title: Acting Chief Financial Officer

Dated: August 15, 2024

v3.24.2.u1
Document and Entity Information
Aug. 13, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 13, 2024
Entity File Number 001-32587
Entity Registrant Name ALTIMMUNE, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-2726770
Entity Address State Or Province MD
Entity Address, Address Line One 910 Clopper Road
Entity Address, Adress Line Two Suite 201S
Entity Address, City or Town Gaithersburg
Entity Address, Postal Zip Code 20878
City Area Code 240
Local Phone Number 654-1450
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ALT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001326190
Amendment Flag false
Pre-commencement Issuer Tender Offer false
Pre-commencement Tender Offer false
Soliciting Material false
Written Communications false
v3.24.2.u1
Document Information
Aug. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment false
CIK 0001326190
Registrant Name ALTIMMUNE, INC.
Period End Date Aug. 13, 2024

Altimmune (NASDAQ:ALT)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024 Haga Click aquí para más Gráficas Altimmune.
Altimmune (NASDAQ:ALT)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024 Haga Click aquí para más Gráficas Altimmune.